8-K
Cocrystal Pharma, Inc. (COCP)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM8-K
CURRENTREPORT
Pursuantto Section 13 or 15(d) of The Securities Exchange Act of 1934
Dateof Report (Date of earliest event reported): June 9, 2020
CocrystalPharma, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-38418 | 35-2528215 |
|---|---|---|
| (State<br> or other Jurisdiction<br><br> <br>of<br> Incorporation) | (Commission<br><br> <br>File<br> Number) | (IRS<br> Employer<br><br> <br>Identification<br> No.) |
| 19805<br> N. Creek Parkway<br><br> <br>Bothell,<br> WA | 98011 | |
| --- | --- | |
| (Address<br> of principal executive offices) | (Zip<br> Code) |
Registrant’s telephone number, including area code: (786) 459-1831
(Former name or former address, if changed since last report.):
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| [ ] | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock | COCP | The<br> Nasdaq Stock Market LLC <br><br> (The Nasdaq Capital Market) |
Item5.07 Submission of Matters to a Vote of Security Holders.
On June 9, 2020, the 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”) was held. At the 2020 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s Board of Directors for a one-year term expiring at the next annual meeting of stockholders (Proposal 1), and (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2), as described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020.
Set forth below are the voting results on each matter submitted to the stockholders at the 2020 Annual Meeting.
Proposal
- The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next annual meeting of stockholders:
| Nominee | Votes For | Votes Withheld | Broker<br><br> Non-Votes | |||
|---|---|---|---|---|---|---|
| Dr. Gary Wilcox | 14,611,420 | 11,316,974 | 15,214,675 | |||
| Dr. Phillip Frost | 14,557,109 | 11,371,285 | 15,214,675 | |||
| Mr. Roger Kornberg | 14,571,489 | 11,356,905 | 15,214,675 | |||
| Mr. Steven Rubin | 11,456,705 | 14,471,689 | 15,214,675 | |||
| Dr. Anthony Japour | 25,812,820 | 115,574 | 15,214,675 |
All five nominees were elected as directors.
Proposal 2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020.
| Votes For | Votes Against | Abstentions | |||
|---|---|---|---|---|---|
| 37,659,301 | 1,163,991 | 2,319,777 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cocrystal Pharma, Inc. | ||
|---|---|---|
| Date:<br> June 15, 2020 | By: | /s/ James Martin |
| Name: | James<br> Martin | |
| Title: | Chief<br> Financial Officer |